Two of these mutations, PTEN Y68H and PTEN R173C, are known to inhibit the activity of the phosphatase catalytic domain of PTEN [41] and occur frequently in gliomas and endometrial cancers [42]. This evidence concerns the gene PTEN and central nervous system cancer.